A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007)
Public ClinicalTrials.gov record NCT06113328. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MK-6194 in Adult Participants With Non-Segmental Vitiligo
Study identification
- NCT ID
- NCT06113328
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Enrollment
- 169 participants
Conditions and interventions
Conditions
Interventions
- MK-6194 Biological
- Placebo Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 26, 2023
- Primary completion
- Mar 19, 2025
- Completion
- Jul 29, 2025
- Last update posted
- Mar 16, 2026
2023 – 2025
United States locations
- U.S. sites
- 13
- U.S. states
- 12
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Cahaba Dermatology & Skin Health Center ( Site 0127) | Birmingham | Alabama | 35244 | — |
| Burke Pharmaceutical Research ( Site 0124) | Hot Springs | Arkansas | 71913 | — |
| The Vitiligo & Pigmentation Institute of Southern California ( Site 0115) | Los Angeles | California | 90036 | — |
| Indiana University Health University Hospital-Indiana University School of Medicine, Department of ( | Indianapolis | Indiana | 46202 | — |
| Dawes Fretzin Clinical Research Group, LLC ( Site 0106) | Indianapolis | Indiana | 46250 | — |
| Metro Boston Clinical Partners ( Site 0110) | Brighton | Massachusetts | 02135 | — |
| Hamzavi Dermatology - Canton ( Site 0101) | Canton | Michigan | 48187 | — |
| Remington Davis Clinical Research-Outpatient ( Site 0104) | Columbus | Ohio | 43215 | — |
| Medical University of South Carolina-Dermatology Research ( Site 0114) | Charleston | South Carolina | 29425 | — |
| International Clinical Research - Tennessee LLC ( Site 0120) | Murfreesboro | Tennessee | 37130 | — |
| Progressive Clinical Research ( Site 0108) | San Antonio | Texas | 78213 | — |
| Virginia Clinical Research, Inc. ( Site 0109) | Norfolk | Virginia | 23502 | — |
| Dermatology Specialists of Spokane ( Site 0126) | Spokane | Washington | 99202 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 55 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06113328, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 16, 2026 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06113328 live on ClinicalTrials.gov.